Abstract: A 54-year-old man diagnosed with HBeAg-positive chronic hepatitis B (CHB) was treated with entecavir (ETV) 1mg/day following an initial unsuccessful lamivudine (LAM) treatment (rtL180M, rtM204V/I).
Abstract: However, this patient experienced virological breakthrough under TDF with a HBV strain bearing rtL80M, rtL180M, rtM204V/I, rtA200V, rtF221Y, rt PMID: 24861361
2014
Journal of medical virology
Abstract: Tenofovir disoproxil fumarate (TDF) is recommended as treatment for chronic hepatitis B patients harboring lamivudine-associated resistance mutations (LAM-R, rtM204V/I +- rtL180M).
Hepatitis B and Delta virus are prevalent but often subclinical co-infections among HIV infected patients in Guinea-Bissau, West Africa: a cross-sectional study.
Abstract: Among 9 patients on antiretroviral treatment (ART), one patient had the [L180M, M204V] mutation associated with lamivudine resistance.
Result: Among 9 patients on ART, one patient had the [L180M, M204V] mutations conferring resistance to lamivudine.
Table: L180M
Discussion: However, only one patient with possibly lamivudine induced resistance [L180M,M204V] mutation was found suggesting that the majority of patients had low HBV DNA levels when ART was commenced.
Discussion: Tripple [M204V, L180M, V173L] mutation has been associated with vaccine escape mutants.
Impact of the rtI187V polymerase substitution of hepatitis B virus on viral replication and antiviral drug susceptibility.
PMID: 25028473
2014
The Journal of general virology
Abstract: Replication-competent HBV constructs containing rtI187V and combined with LAM-resistant (rtM204I, rtL180M/rtM204V) mutations were generated, and compared with WT, LAM-resistant single (rtM204I) or double (rtL180M/rtM204V) and ADV-resistant (rtN236T) clones.
Virologic breakthrough in a patient with chronic hepatitis B by combination treatment with tenofovir disoproxil fumarate and entecavir.
PMID: 25061278
2014
Drug design, development and therapy
Abstract: Amino acid substitutions of rtL180M, rtS202G, and rtM204V emerged and were associated with an increase in serum HBV DNA at virologic breakthrough.
Abstract: At the start of combination therapy, amino acid substitutions of the reverse transcriptase (rt) gene, rtL180M, rtT184I/M, and rtM204V, were detected.
Conclusion: In comparison with those at the start of TDF therapy, the amino acid substitutions changed from rt
Occult hepatitis B virus infection among blood donors in Colombia.
Abstract: Compared to the wt virus, the capacity of virus replication was reduced in most LAMr and ETVr mutants except those with mutations rtM(204V+L180M+V173L), and was similary in the ADVr mutants except rt(A121V+N236T).
A case of entecavir resistance which is developed after complete viral suppression during entecavir treatment for nucleoside-naive chronic hepatitis B.
PMID: 25910308
2014
The Turkish journal of gastroenterology
Abstract: The ETVr-related substitution (rtS202P) and lamivudine resistance-related substitutions (rtL180M+rtM204V) were detected by DNA sequencing analysis at week 145.
Establishment of drug-resistant HBV small-animal models by hydrodynamic injection.
Result: compared with wild-type mouse model, viral replication decreases about 10.06-fold in the rtL180M-rtM204V double mutants, but increases about 7.79-fold in the rtL180M-rtM204V-rtV173L triple mutants.
Result: suggesting that rtM204V and rtL180M double mutations in LAM-resistant HBV mutants resulted in the decline of replication ability, but the third compensatory rtV173L mutation significantly increased the HBV replication ab
Nucleoside/nucleotide analog inhibitors of hepatitis B virus polymerase: mechanism of action and resistance.
Abstract: Major mutational patterns conferring nucleoside/nucleotide analog resistance include the combinations rtL180M/rtM204(I/V) (for lamivudine, entecavir, telbivudine and clevudine) and rtA181V/rtN236T (for adefovir and tenofovir).
HBV mutation literature information.
PMID: 
2014
Journal of clinical virology
Browser Board
Co-occurred Entities
Filtrator
ViMRT